The 16th episode of our podcast, Disrupt, is now available!

Since joining Amedisys (Nasdaq: AMED) in 2014, CEO Paul Kusserow has spearheaded an ambitious turnaround effort, during which time the company’s stock has climbed from around $20 per share to the $130 per share range it sits at today.

Most of Amedisys’ growth over the years has come organically, though the Baton Rouge, Louisiana-based company has been active on the M&A front as well, reflected by its two recent hospice deals.

Listen to this episode of Disrupt to learn:

• What Amedisys is doing to prepare for PDGM
• How the company has grown over the last four years
• Why Amedisys is becoming an even bigger hospice player
• … And much more!

Subscribe to Disrupt to be notified when new episodes are released. Listen today!

Apple Podcasts
Google Play
SoundCloud

Disrupt is exclusively sponsored by